| 1 |
Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and non-adherence[J]. Am J Transplant, 2012, 12(2): 388-399.
|
| 2 |
Kean JM, Rao S, Wang M, et al. Seroepidemiology of human polyomaviruses[J]. PLoS Pathog, 2009, 5(3): e1000363.
|
| 3 |
Garces JC. BK virus-associated nephropathy in kidney transplant recipients[J]. Ochsner J, 2010, 10(4): 245-249.
|
| 4 |
Elfadawy N, Flechner SM, Liu X, et al. The impact of surveillance and rapid reduction in immunosuppression to control BK virus-related graft injury in kidney transplantation[J]. Transplant Int, 2013, 26(8): 822-832.
|
| 5 |
Weiss AS, Gralla J, Chan L, et al. Aggressive immunosuppression minimization reduces graft loss following diagnosis of BK virus-associated nephropathy: a comparison of two reduction strategies[J]. Clin J Am Soc Nephrol, 2008, 3(6): 1812-1819.
|
| 6 |
Hardinger KL, Koch MJ, Bohl DJ, et al.BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results[J]. Am J Transplant, 2010, 10(2): 407-415.
|
| 7 |
Hirsch HH, Vincenti F, Friman S, et al. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study[J]. Am J Transplant, 2013, 13(1): 136-145.
|
| 8 |
Schaub S, Hirsch HH, Dickenmann M, et al. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy[J]. Am J Transplant, 2010, 10(12): 2615-2623.
|
| 9 |
Petrov R, Elbahloul O, Gallichio MH, et al. Monthly screening for polyoma virus eliminates BK nephropathy and preserves renal function[J]. Surg Infect (Larchmt), 2009, 10(1): 85-90.
|
| 10 |
Hodowanec AC, Simon DM. BK virus screening and management practices among US renal transplant programs: a survey[J]. Transpl Int, 2015, 28(11): 1339-1341.
|
| 11 |
Leboeuf C, Wilk S, Achermann R, et al. BK polyomavirus-specific 9mer CD8 T cell responses correlate with clearance of BK viremia in kidney transplant recipients: first report from the Swiss transplant cohort study[J]. Am J Transplant, 2017, 17(10): 2591-2600.
|
| 12 |
Bischof N, Hirsch HH, Wehmeier C, et al. Reducing calcineurin inhibitor first for treating BK polyomavirus replication after kidney transplantation: long-term outcomes[J]. Nephrol Dial Transplant, 2019, 34(7): 1240-1250.
|
| 13 |
Höcker B, Schneble L, Murer L, et al. Epidemiology of and risk factors for BK polyomavirus replication and nephropathy in pediatric renal transplant recipients: an International CERTAIN Registry Study[J]. Transplantation, 2019, 103(6): 1224-1233.
|
| 14 |
Schachtner T, Babel N, Reinke P. Different risk factor profiles distinguish early onset from late onset BKV-replication[J]. Transpl Int, 2015, 28(9): 1081-1091.
|
| 15 |
Imlay H, Whitaker K, Fisher CE, et al. Clinical characteristics and outcomes of late-onset BK virus nephropathy in kidney and kidney-pancreas transplant recipients[J]. Transpl Infect Dis, 2018, 20(4): e12928.
|
| 16 |
Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction[J]. Am J Transplant, 2005, 5(3): 582-594.
|
| 17 |
Schwarz A, Linnenweber-Held S, Heim A, et al. Viral origin, clinical course, and renal outcomes in patients with BK virus infection after living-donor renal transplantation[J]. Transplantation, 2016, 100(4): 844-853.
|
| 18 |
Pang XL, Doucette K, LeBlanc B, et al. Monitoring of polyomavirus BK virus viruria and viremia in renal allograft recipients by use of a quantitative real time PCR assay: one year prospective study[J]. J Clin Microbiol, 2007, 45(11): 3568-3573.
|
| 19 |
Funk GA, Gosert R, Comoli P, et al. Polyomavirus BK replication dynamics in vivo and in silico to predict cytopathology and viral clearance in kidney transplants[J]. Am J Transplant, 2008, 8(11): 2368-2377.
|
| 20 |
Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations[J]. Transplantation, 2005, 79(10): 1277-1286.
|
| 21 |
Bicalho CS, Oliveira RDR, David DR, et al. Determination of viremia cut-off for risk to develop BKPyV-associated nephropathy among kidney transplant recipients[J]. Transpl Infect Dis, 2018, 20(5): e12969.
|
| 22 |
Sood P, Senanayake S, Sujeet K, et al. Management and outcome of BK viremia in renal transplant recipients: a prospective single center study[J]. Transplantation, 2012, 94(8): 814-821.
|
| 23 |
Hirsch HH, Drachenberg CB, Steiger J, et al. Polyomavirus-associated nephropathy in renal transplantation: critical issues of screening and management[J]. Adv Exp Med Biol, 2006, 577: 160-173.
|
| 24 |
Pollara CP, Corbellini S, Chiappini S, et al. Quantitative viral load measurement for BKV infection in renal transplant recipients as a predictive tool for BKVAN[J]. New Microbiol, 2011, 34(2): 165-171.
|
| 25 |
Johnston O, Jaswal D, Gill JS, et al. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review[J]. Transplantation, 2010, 89(9): 1057-1070.
|
| 26 |
Ginevri F, Azzi A, Hirsch HH, et al. Prospective monitoring of polyomavirus BK replication and impact of preemptive intervention in pediatric kidney recipients[J]. Am J Transplant, 2007, 7(12): 2727-2735.
|
| 27 |
Saad ER, Bresnahan BA, Cohen EP, et al. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy[J]. Transplantation, 2008, 85(6): 850-854.
|
| 28 |
Huang G, Wang CX, Zhang L, et al. Monitoring of polyomavirus BK replication and impact of preemptive immunosuppression reduction in renal transplant recipients in China: a 5-year single-center analysis[J]. Diagn Microbiol Infect Dis, 2015, 81(1): 21-26.
|
| 29 |
Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival[J]. N Engl J Med, 2013, 369(13): 1215-1226.
|
| 30 |
Krisl JC, Taber DJ, Pilch N, et al. Leflunomide efficacy and pharmacodynamics for the treatment of BK viral infection[J]. Clin J Am Soc Nephrol, 2012, 7(6): 1003-1009.
|
| 31 |
Hirsch HH, Randhawa PS, AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9): e13528.
|